Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI
Adverse events: malignancy · kidney transplant recipients
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).
1 finding from 1 review
- Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes onlyRR 1.22 [0.42, 3.52]5 studies · 1074 participantsLow